{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:31:46Z","timestamp":1788820306636,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Introduction: Recombinant human deoxyribonuclease I (rhDNase) cleaves DNA in mucus, facilitating increased mucociliary clearance of purulent sputum. In cystic fibrosis (CF), rhDNase improves pulmonary function and decreases exacerbations. Conversely, rhDNase use in non-CF bronchiectasis (NCFB) patients has not yielded similarly effective results. We explored the safety and feasibility of rhDNase in patients with bronchiectasis due to primary ciliary dyskinesia (PCD). Methods: In this real-life pilot study, patients with PCD received rhDNase to treat viscous mucus. We compared pulmonary function tests and pulmonary exacerbations for these patients over six months of use of rhDNase. Results: Eight PCD patients with symptomatic bronchiectasis commenced use of rhDNase at variable dosing (ranging from at least twice weekly to a full 2.5 mg dose daily). Over a six-month period, pulmonary function tests, as measured by mean FVC and FEV1, remained relatively stable compared to prior to commencing rhDNase. Mean pulmonary exacerbations decreased from 3.1 to 2.3 in the six-month period after commencing rhDNase, as compared to the six-month period prior to rhDNase. Conclusions: Use of rhDNase in PCD patients was safe and did not adversely impact lung function or increase pulmonary exacerbations, in contrast to earlier trial results in NCFB patients with heterogeneous etiologies. Further clinical data is required to identify the population of PCD patients who can benefit from rhDNase, as well as the appropriate dosing and timing.<\/jats:p>","DOI":"10.3390\/medsci14010133","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:12:24Z","timestamp":1773321144000},"page":"133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Recombinant Human Deoxyribonuclease I in Primary Ciliary Dyskinesia Bronchiectasis\u2014A Real Life Pilot Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-3973","authenticated-orcid":false,"given":"Moshe","family":"Heching","sequence":"first","affiliation":[{"name":"Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel"},{"name":"Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora","family":"Slomianksy","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-9657","authenticated-orcid":false,"given":"Eviatar","family":"Naamany","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel"},{"name":"Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai R.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel"},{"name":"Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S2213-2600(19)30374-1","article-title":"Primary ciliary dyskinesia in the genomics age","volume":"8","author":"Lucas","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-Obstructive lung diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1183\/13993003.01390-2015","article-title":"Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia","volume":"47","author":"Ratjen","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.chest.2019.06.012","article-title":"The emerging role of neutrophil extracellular traps in respiratory disease","volume":"156","author":"Twaddell","year":"2019","journal-title":"CHEST"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1165\/rcmb.2020-0168OC","article-title":"Neutrophil extracellular traps increase airway mucus viscoelasticity and slow mucus particle transit","volume":"64","author":"Linssen","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/17476348.1.3.317","article-title":"Pharmacology, clinical efficacy and safety of recombinant human DNase in cystic fibrosis","volume":"1","author":"Bakker","year":"2007","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_7","first-page":"CD001127","article-title":"Dornase alfa for cystic fibrosis","volume":"3","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I","volume":"113","author":"Barker","year":"1998","journal-title":"CHEST"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.2025.2680","article-title":"Non-cystic fibrosis bronchiectasis in adults: A review","volume":"334","author":"Barker","year":"2025","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.1950200509","article-title":"Clinical benefit from nebulized human recombinant DNase in Kartagener\u2019s syndrome","volume":"20","author":"Desai","year":"1995","journal-title":"Pediatr. Pulmonol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<59::AID-PPUL11>3.0.CO;2-D","article-title":"DNase treatment in primary ciliary dyskinesia\u2014Assessment by nocturnal pulse oximetry","volume":"27","author":"Brinkhorst","year":"1999","journal-title":"Pediatr. Pulmonol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.rmed.2007.05.014","article-title":"Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia","volume":"101","author":"Clifton","year":"2007","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"for the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240179","DOI":"10.1183\/16000617.0179-2024","article-title":"Neutrophilic inflammation in bronchiectasis","volume":"34","author":"Chalmers","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17476348.2024.2394694","article-title":"The continuing need for dornase alfa for extracellular airway DNA hydrolysis in the era of CFTR modulators","volume":"18","author":"Roesch","year":"2024","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12931-022-02280-7","article-title":"Sputum from patients with primary ciliary dyskinesia contains high numbers of dysfunctional neutrophils and inhibits efferocytosis","volume":"23","author":"Blanter","year":"2022","journal-title":"Respir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/cmi.2017.118","article-title":"Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: Key players in chronic respiratory diseases","volume":"15","author":"Cockx","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1378\/chest.129.1.118","article-title":"Mucus properties in children with primary ciliary dyskinesia: Comparison with cystic fibrosis","volume":"129","author":"Bush","year":"2006","journal-title":"CHEST"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.prrv.2008.11.003","article-title":"Primary ciliary dyskinesia: Prospects for new therapies, building on the experience in cystic fibrosis","volume":"10","author":"Amirav","year":"2009","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","article-title":"Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis","volume":"201","author":"Ramsey","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","first-page":"2500616","article-title":"Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"18","author":"Nussstein","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ppul.23897","article-title":"Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change","volume":"53","author":"VanDevanter","year":"2018","journal-title":"Pediatr. Pulmonol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:57:38Z","timestamp":1773323858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medsci14010133"],"URL":"https:\/\/doi.org\/10.3390\/medsci14010133","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}